← FDA DRUG APPROVALS

FDA ANDA · ANDA089565

VINBLASTINE SULFATE

Sponsor: HOSPIRA

APPLICATION
ANDA089565
TYPE
ANDA
ORIGINAL APPROVAL
1987-08-18
LATEST ACTION
2001-09-25
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

VINBLASTINE SULFATEDiscontinued
VINBLASTINE SULFATE 10MG/VIAL · INJECTABLE · INJECTION

Approval history

2001-09-25Labeling · Supplement 22AP
2001-07-30Manufacturing (CMC) · Supplement 21AP
2001-05-14Manufacturing (CMC) · Supplement 20AP
2000-08-08Manufacturing (CMC) · Supplement 18AP
2000-05-18Manufacturing (CMC) · Supplement 17AP
2000-05-12Manufacturing (CMC) · Supplement 16AP
1997-09-11Labeling · Supplement 13AP
1995-04-28Manufacturing (CMC) · Supplement 12AP
1995-01-11Labeling · Supplement 11AP
1993-04-14Labeling · Supplement 9AP
1993-04-14Labeling · Supplement 10AP
1992-12-23Manufacturing (CMC) · Supplement 5AP
1992-12-23Manufacturing (CMC) · Supplement 6AP
1992-09-30Manufacturing (CMC) · Supplement 3AP
1992-09-30Labeling · Supplement 8AP
1992-07-22Manufacturing (CMC) · Supplement 7AP
1990-01-12Labeling · Supplement 4AP
1989-09-22Labeling · Supplement 2AP
1988-05-23Manufacturing (CMC) · Supplement 1AP
1987-08-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →